Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

LENZ Therapeutics (LENZ) Other Accumulated Expenses (2022 - 2023)

LENZ Therapeutics (LENZ) has disclosed Other Accumulated Expenses for 2 consecutive years, with $221000.0 as the latest value for Q3 2023.

  • Quarterly Other Accumulated Expenses fell 53.77% to $221000.0 in Q3 2023 from the year-ago period, while the trailing twelve-month figure was $221000.0 through Sep 2023, down 53.77% year-over-year, with the annual reading at $1.4 million for FY2022, N/A changed from the prior year.
  • Other Accumulated Expenses for Q3 2023 was $221000.0 at LENZ Therapeutics, down from $3.1 million in the prior quarter.
  • The five-year high for Other Accumulated Expenses was $4.9 million in Q1 2023, with the low at $179000.0 in Q2 2022.